Shionogi said on February 22 that it has received European regulatory approval for its opioid-induced constipation (OIC) treatment naldemedine, which will be marketed under the trade name of Rizmoic. The European Commission cleared the drug for the treatment of OIC…
To read the full story
Related Article
- Shionogi Hooks Up with Ferrer to Promote Rizmoic in Spain
June 25, 2019
- Shionogi in Marketing Tie-Up with Molteni for Rizmoic
May 23, 2019
- Shionogi Earns CHMP OK for Naldemedine
December 19, 2018
BUSINESS
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
- PeptiDream Poaches 3 EVPs to Bolster Global Expansion
July 3, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





